Why the study?
Does new-onset LBBB after TAVR worsen clinical outcomes (death, hospitalization, stroke, MI) at 1 year in patients without baseline intraventricular conduction delay?
Does new-onset LBBB after TAVR worsen clinical outcomes (death, hospitalization, stroke, MI) at 1 year in patients without baseline intraventricular conduction delay?
New-onset LBBB after TAVR does not increase 1-year mortality or hard ischemic events, but increases the need for permanent pacemakers and blunts LVEF recovery.
New LBBB after TAVR signals higher PPI need without raising 1-year hard events; leaves open whether it warrants targeted LVEF interventions.
Persistent, new-onset LBBB occurred in 10.5% of patients without intraventricular baseline conduction who underwent TAVR in the PARTNER experience. New LBBB was not associated with death, repeat hospitalization, stroke, or myocardial infarction at 1 year, but was associated with a higher rate of PPI and failure of left ventricular ejection fraction to improve.
No takes yet. Share an insight, caveat, or question.
Nazif et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: